Corvus Pharmaceuticals (CRVS) Long-Term Investments (2020 - 2026)

Corvus Pharmaceuticals' Long-Term Investments history runs 7 years deep, the most recent figure standing at $10.5 million for Q1 2026.

• In Q1 2026, Long-Term Investments fell 12.95% year-over-year to $10.5 million; the TTM figure through Mar 2026 stood at $10.5 million (down 12.95% YoY), while the FY2025 annual figure was $11.0 million, down 12.35% from the prior year.
• Long-Term Investments for Q1 2026 stood at $10.5 million, down from $11.0 million in the prior quarter.
• The five-year high for Long-Term Investments was $33.4 million in Q1 2022, with the low at $10.5 million in Q1 2026.
• The 5-year median for Long-Term Investments is $16.1 million (2024), against an average of $17.6 million.
• The sharpest annual moves came in 2022 and 2023: Long-Term Investments declined 10.11% in 2022, then sank 40.3% in 2023.
• Corvus Pharmaceuticals' Long-Term Investments stood at $21.9 million in 2022, then dropped by 26.3% to $16.1 million in 2023, then fell by 22.22% to $12.5 million in 2024, then declined by 12.35% to $11.0 million in 2025, then fell by 4.5% to $10.5 million in 2026.
• Business Quant data shows CRVS's Long-Term Investments at $10.5 million in Q1 2026, $11.0 million in Q4 2025, and $11.5 million in Q3 2025.